An RNA-seq study in Friedreich ataxia patients identified hsa-miR-148a-3p as a putative prognostic biomarker of the disease

Abstract Friedreich ataxia (FRDA) is a life-threatening hereditary ataxia; its incidence is 1:50,000 individuals in the Caucasian population. A unique therapeutic drug for FRDA, the antioxidant Omaveloxolone, has been recently approved by the US Food and Drug Administration (FDA). FRDA is a multi-sy...

Full description

Bibliographic Details

Published in:	Human Genomics
Main Authors:	Chiara Vancheri, Andrea Quatrana, Elena Morini, Caterina Mariotti, Alessia Mongelli, Mario Fichera, Alessandra Rufini, Ivano Condò, Roberto Testi, Giuseppe Novelli, Florence Malisan, Francesca Amati
Format:	Article
Language:	English
Published:	BMC 2024-05-01
Subjects:	microRNA RNA-seq Biomarkers Friedreich ataxia Frataxin
Online Access:	https://doi.org/10.1186/s40246-024-00602-y